Objective To explore the clinical efficacy of combination of ticagrelor and aspirin in the treatment of myocardial infarction. Methods 86 patients with myocardial infarction were studied,and were divided into two groups by different treatment methods,among which 43 patients treated with combination of ticagrelor and aspirin were selected as the study group,and the other 43 patients treated with aspirin as the control group. The inflammatory factors,cardiac function indicators,myocardial enzyme indicators,N-terminal pro-brain natriuretic peptide (NT-proBNP) and incidence of adverse events were compared between the two groups. Results After treatment,the C-reactive protein (CRP),tumor necrosis factor-α(TNF-α) and interleukin6 (IL-6) were (27.30±2.95) mg/L,(2.15±0.30) ng/L and (170.00±10.81) ng/L in the study group,which were lower than (33.08±3.14) mg/L,(3.00±0.71) ng/L and (180.72±11.54) ng/L in the control group,and the difference was significant (P<0.05). After treatment,the left ventricular ejection fraction (LVEF) of (46.41±2.14)％ in the study group was higher than (42.90±2.00)％ in the control group;the left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) in the study group were (34.47±0.42) and (58.22±2.58) mm,which were lower than (36.99±0.99) and (60.02±3.01) mm in the control group;the difference was significant (P<0.05). After treatment,NT-proBNP of the study group was (119.77±50.47) pg/ml,the creatine kinase isoenzyme (CK-MB) was (30.45±1.99) U/L,and the troponin Ⅰ (cTnI) was (0.58±0.03) μg/L,which were lower than (388.87±100.24) pg/ml,(37.47±2.57) U/L,and (0.92±0.06) μg/L of the control group,and the difference was significant (P<0.05). The incidence of adverse events of 6.98％ in the study group was significantly lower than 23.26％ in the control group (P<0.05). Conclusion The combination of ticagrelor and aspirin has significant clinical efficacy in the treatment of myocardial infarction,which can improve the cardiac function indicators of patients,enhance their vascular endothelial function,reduce the incidence of adverse events,and has superior performance in platelet aggregation function,which is worthy of clinical promotion and use of this combination regimen.
维普
万方数据
